Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.

Terminated 100 enrolled Alexion Pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection.

Timeline

Start: —
Primary completion: —
Completion: 2003-05

Outcome

Outcome not reported

Stopped: “Safety concerns from other studies.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Elvucitabine	Small molecule	5 mg	—

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.

Summary

Timeline

Outcome

Drugs

Indications